RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BORELLI B
Collezione AO Cuneo

Items : 4

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.

2019
AO Cuneo

Lonardi S; Sensi E; Tonini G; Di Donato S; Schirripa M; Delfanti S; Granetto C; Gemma D; Casagrande M; Borelli B; Allegrini G; Murgioni S; Antoniotti C; Dell'Aquila E; Salvatore L; Masi G; Aprile G; Bergamo F; Cremolini C; Marmorino F; Fontanini G; Boni L; Falcone A;

Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403.

2019
AO Cuneo

Marmorino F; Rossini D; Lonardi S; Moretto R; Zucchelli G; Aprile G; Dell'Aquila E; Ratti M; Bergamo F; Masi G; Urbano F; Ronzoni M; Libertini M; Borelli B; Randon G; Buonadonna A; Allegrini G; Pella N; Ricci V; Boccaccino A; Latiano TP; Cordio S; Passardi A; Tamburini E; Boni L; Falcone A; Cremolini C; Marmorino F; Rossini D; et alii...

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. in Oncotarget / Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

2018
AO Cuneo
AOU Città della Salute di Torino

Danesi R; Falcone A; Boni L; Zagonel V; Di Donato S; Buonadonna A; Allegrini G; Ricci V; Racca P; Ronzoni M; Tomasello G; Zaniboni A; Moretto R; Cortesi E; Citi V; Marmorino F; Borelli B; Loupakis F; Bergamo F; Antoniotti C; Lonardi S; Del Re M; Cremolini C;

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer. in ESMO open / ESMO Open. 2018 Jul 9;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018.

2018
AO Cuneo

Borelli B; Moretto R; Lonardi S; Bonetti A; Antoniotti C; Pietrantonio F; Masi G; Burgio V; Marmorino F; Salvatore L; Rossini D; Zaniboni A; Zucchelli G; Martignetti A; Di Battista M; Pella N; Passardi A; Boccaccino A; Leone F; Colombo C; Granetto C; Vannini F; Marsico VA; Martinelli E; Antonuzzo L; Vitello S; Delliponti L; Boni L; Cremolini C; et alii...